Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2009

01-08-2009 | Epidemiology

Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients

Authors: Nan-Yan Rao, Zhen Hu, Jin-Ming Yu, Wen-Feng Li, Bin Zhang, Feng-Xi Su, Jiong Wu, Zhen-Zhou Shen, Wei Huang, Zhi-Ming Shao

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Login to get access

Abstract

Purpose Established models (Penn, Myraid and BRCApro) are useful of estimating the probability that a person has a BRCA mutation. But the value of these models in Chinese population is unclear. The aim of the study is to evaluate the performance of three models on the assisting in pre-test genetic risk counseling. Methods Three risk assessment models, Penn II, Myriad and BRCApro, were applied to 212 familial breast cancer patients who had undergone BRCA1/2 mutation analysis. Sensitivity, specificity, positive and negative predictive values, likelihood ratios and area under the receiver operator characteristic (ROC) curve were calculated for each model. Results Myriad showed a better ROC curve than BRCApro either for BRCA1 or BRCA1/2 combination mutation prediction, but BRCApro had a higher positive likelihood ratio when using 10% as the probability threshold. The performance of three models improved when they were evaluated in 66 patients from high risk families, presenting increased ROC and positive likelihood ratio. Especially that of BRCApro for BRCA2, the ROC was increased to 0.716 and its positive likelihood was 5.6. Conclusion Three models had the similar impact on the pre-test probability of BRCA mutation. But at a 10% cutoff point, BRCApro had the best BRCA mutation carrier prediction value. The performance of BRCApro for BRCA2 mutation prediction was improved when it was restricted in patients from high risk families.
Appendix
Available only for authorised users
Literature
7.
go back to reference Nelson HD, Huffman LH, Fu R et al (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 143:362–379PubMed Nelson HD, Huffman LH, Fu R et al (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 143:362–379PubMed
10.
11.
12.
go back to reference Evans DG, Neuhausen SL, Bulman M (2004) Haplotype and cancer risk analysis of two common mutations, BRCA1 4184del4 and BRCA2 2157delG, in high risk northwest England breast/ovarian families. J Med Genet 41:e21. doi:10.1136/jmg.2003.012104 PubMedCrossRef Evans DG, Neuhausen SL, Bulman M (2004) Haplotype and cancer risk analysis of two common mutations, BRCA1 4184del4 and BRCA2 2157delG, in high risk northwest England breast/ovarian families. J Med Genet 41:e21. doi:10.​1136/​jmg.​2003.​012104 PubMedCrossRef
13.
go back to reference Li WF, Hu Z, Rao NY et al (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110:99–109PubMedCrossRef Li WF, Hu Z, Rao NY et al (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110:99–109PubMedCrossRef
14.
go back to reference Szabo C, Masiello A, Ryan JF et al (2000) The breast cancer information core: database design, structure, and scope. Hum Mutat 16:123–131. doi:10.1002/1098-1004(200008)16:<123::AID-HUMU4>3.0.CO;2-YPubMedCrossRef Szabo C, Masiello A, Ryan JF et al (2000) The breast cancer information core: database design, structure, and scope. Hum Mutat 16:123–131. doi:10.1002/1098-1004(200008)16:<123::AID-HUMU4>3.0.CO;2-YPubMedCrossRef
15.
go back to reference den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 15:7–12. doi:10.1002/(SICI)1098-1004(200001)15:1<7::AID-HUMU4>3.0.CO;2-NCrossRef den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 15:7–12. doi:10.1002/(SICI)1098-1004(200001)15:1<7::AID-HUMU4>3.0.CO;2-NCrossRef
16.
go back to reference DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845. doi:10.2307/2531595 PubMedCrossRef DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845. doi:10.​2307/​2531595 PubMedCrossRef
23.
go back to reference Evans JP, Skrzynia C, Susswein L et al (2005) Genetics and the young woman with breast cancer. Breast Dis 23:17–29PubMed Evans JP, Skrzynia C, Susswein L et al (2005) Genetics and the young woman with breast cancer. Breast Dis 23:17–29PubMed
25.
26.
go back to reference Machado PM, Brandao RD, Cavaco BM et al (2007) Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027–2034. doi:10.1200/JCO.2006.06.9443 PubMedCrossRef Machado PM, Brandao RD, Cavaco BM et al (2007) Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027–2034. doi:10.​1200/​JCO.​2006.​06.​9443 PubMedCrossRef
27.
go back to reference Puget N, Stoppa-Lyonnet D, Sinilnikova OM et al (1999) Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res 59:455–461PubMed Puget N, Stoppa-Lyonnet D, Sinilnikova OM et al (1999) Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res 59:455–461PubMed
28.
go back to reference Euhus DM, Smith KC, Robinson L et al (2002) Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCApro. J Natl Cancer Inst 94:844–851PubMed Euhus DM, Smith KC, Robinson L et al (2002) Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCApro. J Natl Cancer Inst 94:844–851PubMed
Metadata
Title
Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients
Authors
Nan-Yan Rao
Zhen Hu
Jin-Ming Yu
Wen-Feng Li
Bin Zhang
Feng-Xi Su
Jiong Wu
Zhen-Zhou Shen
Wei Huang
Zhi-Ming Shao
Publication date
01-08-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0181-4

Other articles of this Issue 3/2009

Breast Cancer Research and Treatment 3/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine